Robocath

About the deal

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.

This acquisition significantly strengthens Stereotaxis’ position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.